Cytokinetics Incorporated
Officers & Directors
Executive Team: - Robert I. Blum, President, Chief Executive Officer, and Director (Principal Executive Officer) - Robert C. Wong, Vice President, Chief Accounting Officer (Principal Accounting Officer) Board of Directors: - Santo J. Costa, Director - Robert A. Harrington, M.D., Director - Edward M. Kaye, M.D., Director - Wendell Wierenga, Ph.D., Director - Nancy J. Wysenski, Director - Sandford D. Smith, Director - John T. Henderson, M.B. Ch.B., Chairman of the Board of Directors - Muna Bhanji, Director - B. Lynne Parshall, Director ,
Cytokinetics Incorporated currently has 673 employees.
News about Cytokinetics Incorporated Key Personnel |
Impact Assessment of Cytokinetics’ Strategic Developments and Talent AcquisitionCytokinetics Announces Drug Licensing Deal with SanofiOn December 20, 2024, Cytokinetics, a California-based biopharmaceutical company, announced an exclusive agreement with Sanofi for the development and commercialization of aficamten, a next-in-class cardiac myosin inhibitor. This drug aims to treat patients with both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) in Greater China. Aficamten, sourced from Corxel Pharmaceuticals, has been recognized as a promising therapeutic avenue in the cardiovascular disease space, which could potentially expand the market for Cytokinetics significantly by leveraging Sa...
|
Cytokinetics Boosts Employee Incentives with Inducement Grants in Nasdaq Listing Move
In a move aimed at attracting and retaining top talent, Cytokinetics, Incorporated (Nasdaq: CYTK) has announced the granting of stock options and restricted stock units (RSUs) to 16 newly employed individuals. The inducement grants, made under Nasdaq Listing Rule 5635(C)(4), are intended to serve as a material incentive for these employees, whose tenure with the company commenced in July 2024.
The biopharmaceutical company, headquartered in South San Francisco, has stepped up its efforts to bolster its staff amid an increasingly competitive industry landscape. By providing attractive inducements to new employees, Cy...
|
In an impressive move, Cytokinetics, Incorporated (Nasdaq: CYTK) recently announced the provision of inducement grants to a select group of employees. These grants consist of stock options, restricted stock units (RSUs), and performance stock units (PSUs), demonstrating the company s commitment to attracting and retaining top talent. With a total of 48,453 shares of common stock, 31,460 RSUs, and 5,537 PSUs granted, Cytokinetics aims to motivate and reward these employees, whose employment began in June 2024.
While the announcement of these inducement grants is exciting, it comes at a time when the company is also grappling with financial challenges. Cytokinetics recorded a cumulative net loss ...
|
Cytokinetics, Incorporated, a biopharmaceutical company, recently announced its partnership with the European Organisation for Rare Diseases (EURORDIS) and the National Organization for Rare Disorders (NORD) in support of Rare Disease Day. This international campaign aims to increase awareness and public understanding of rare diseases, highlighting the challenges faced by over 300 million people living with such conditions worldwide. Additionally, Cytokinetics financial performance has been notably affected, as the company recorded a cumulative net loss of $527 million during the 12-month period ending in the third quarter of 2023, contributing to a negative return on investment (ROI) of -67.49%.<...
|
|
|
